Aogenics Group

Overview

Taiwan-based CDMO and biosimilar developer founded in 2012 with eight biosimilars in pipeline and two on market, deriving over 65% of revenue from Japan and international clients. Aogenics Group was established in Taiwan in 2012 after acquiring a biopharmaceutical pilot unit from the government's MOEA/DCB center, which provided the most complete talent pool to start the business. Aogenics has eight biosimilars in its pipeline with two already on the market and derives more than 65% of revenue from outside Taiwan, with Japan as the primary client geography. (Segment 5 (20:00-25:00))